Original title: IBM Watson embarrassing journey in China
Finance Zhang Li / Wen Wang Xiao / Editor
In the twinkling of an IBM blue logo, Li Chunmei's husband, Liu Yinsong, saw the diagnosis and treatment offered by IBM Watson for oncology. The scheme is in line with the recommendation of many experts. However, Li Chunmei and his wife feel that the consultation fee of 6,000 yuan has been drifted away.
For four years, Li Chunmei, 40, has been in Beijing hospitals, undergoing surgery, chemotherapy and radiotherapy, and is currently under the control of the drug Olaparib. She is worried about drug resistance and expects Watson to give her next treatment.
At 10:30 on July 5, 2018, Liu Yinsong took part in the above-mentioned multi-disciplinary consultation on behalf of his wife.
Similarly, Fu Gang, chairman of Baiyang Pharmaceutical Group, also felt the distance between expectation and reality. In an interview with the finance and economics reporter, he said that the progress of WfO promotion in China is not as good as expected.
IBM Watson was once synonymous with AI medicine, but in the past two years, it has been commercialized and promoted in China.
Although Kathy McGroddy, vice president of IBM Watson health, told Fortune that Watson health was not just a revolution in the medical industry, it was also a revolution in IBM itself. Financial data shows that IBM has declined for 21 consecutive quarters.
Over the past two years, IBM has drastically reduced its traditional business, transforming its business architecture from software and hardware services to the cloud recognition industry. Among them, the artificial intelligence cognitive computing platform (IBM Watson) bears all the expectations of the transformation. It is a cognitive technology platform that gathers advanced natural language processing, information retrieval, knowledge representation, automatic reasoning, machine learning and so on.
Although it is the most mature cognitive computing platform, IBM Watson is still a research project. IBM has invested billions of dollars in Watson research and development and access to relevant data / analysis capabilities over the past five years, according to Jefferies, a leading Wall Street investment bank. IBM has not published Watson's financial data yet.
Technology landing, need to find the right application scenarios, industry insight and depth operation. Now the Blue Giant has to answer again how
What is the value of Watson?
Hope never to leave the Liu Yinsong couple, they look forward to new drugs, new therapies on the market, which is also driving them to come to Watson a big reason.
Aulapani, who was recommended by WfO in July, has been taking it since May 15 at the suggestion of her doctor. It is a single drug approved in the United States in 2014 for the treatment of advanced ovarian cancer and is not yet available domestically. The State Drug Administration has included Orapally tablets in the priority review and approval process, and is expected to go on the market within 2018. As for how to buy this drug at this stage, Liu Yinsong smiled with a sly smile and said:
WfO, trained in memory of the four years of Sloan Kettering Cancer Center (MSKCC), has studied more than 300 medical journals, more than 250 medical books, 15 million pages of research data and a large number of clinical cases.
Watson does not include the latest therapies, because the latest therapies haven't produced a lot of data, and each of the recommended therapies has corresponding empirical support. Earlier, the chief medical adviser to IBM Watson Health explained at an industry meeting that Watson would prefer to retain larger, earlier clinical data and conclusions that physicians can see in detail.
Such caution enables the Watson recommendation to be highly consistent with expert diagnosis. The publicity document also illustrates this point, with Watson's cancer treatment and MSKCC experts giving more than 90% of the program accord.
A director of oncology at a third-tier hospital said it was not surprising that Watson was consistent with the expert's diagnosis. The data and analysis process came from guidelines, high-level literature, and experience in high-level hospitals. His guidance to doctors would not be seriously biased.
However, this statement was challenged. According to an unpublished study in Denmark, Watson's diagnostic plan accords with only 30% given by experts, so the hospital refuses to purchase the Watson system.
For the operator, the WfO process is not complex: Doctors input major case characteristics, Watson extracts patient attributes from them, uses these attributes to find clinical guidelines to determine candidate treatment options, and searches evidence databases to find supporting evidence for each option, including complications, contraindications, and MSK optimal treatment. Finally, according to the best evidence, the Watson analysis algorithm takes precedence over the treatment plan.
Doctors have mixed opinions about Watson.
Some experts attach great importance to the medical advice they give.
Wang Taifeng, deputy general manager of Cognitive Care Network Technology Limited, believes that Watson is valuable in all hospitals and can improve the decision-making efficiency of primary doctors. Teaching tools, and find out the deficiencies of Watson, and carry out corresponding training.
And some experts questioned Watson, like a paralegal, whose main skill was to search literature and ask questions about where it should be used.
If Watson could explain how to give a patient's treatment step by step, it would make Liu Yinsong feel more useful.
Watson's treatment plan is only a directional framework, not so detailed as to be used as a treatment plan, which needs to be refined by the physician. According to Liu Yinsong, after the consultation, the doctor privately advised his wife to do drug sensitivity test, which was the biggest benefit of the consultation.
Watson is not acclimatized.
Since 2016, IBM Watson has been introduced into China as a commercialized product. The American IBM Watson has been confronted with many problems, such as the differences in medical systems, models and treatment schemes between China and the United States.
Watson adheres to the multi-disciplinary consultation model, which is also the largest difference in cancer diagnosis and treatment between China and the United States. China is often a single department of war, the U. S. cancer treatment is often multidisciplinary consultation
Last year, Watson landed at the ten hospital in Shanghai. Xu Qing, director of the oncology department of Shanghai Tenth Hospital, told the Financial Journal that if there were no Watson and there was no consensus in the multi-disciplinary consultation, he would eventually listen to the advice of those highly qualified doctors. With Watson, he would have a relatively objective direction to control.
It involves many departments and specialists, which puts forward high requirements for the domestic hospitals with departments as the main body at the present stage.
Over the years, it is difficult for different departments of public hospitals to cooperate with each other, and it is difficult to clarify who organizes and implements their rights and responsibilities. Wang Shun, a deputy general manager and chief medical officer of Shengnuo, told Finance and Economics that foreign medical institutions have tumor centers, including surgeons, radiotherapists, pathologists and other disciplines, while domestic hospitals are tumor surgery, internal medicine and so on. They are independent and can not discuss several cases a week.
WfO now supports 10 cancers, including breast, lung, colon, and rectal cancer, according to a marketing profile obtained by Caijing.
In the consultation held by Liu Yinsong, more than 10 oncologist participated in the consultation. A doctor complains that the doctor is busy with work and tense and needs to waste time in consultation.
Xu Qing introduced that in the ten hospital of Shanghai, the Watson intelligent consultation center has received nearly 500 patients. These patients are mostly men with better economic conditions, or due to difficult and complicated diseases, or consulted many hospital experts, but there are different views, hoping to further clarify the diagnosis and treatment.
WfO consultation is difficult to carry out frequently in the third Class A Hospital, and the daily diagnosis and treatment is limited.
Because of the differences between China and the United States in the prevention of cancer treatment, Watson is also undergoing localization training. However, some scholars believe that Watson should not be too localized. They hope that Watson's proposals will be different from those they have given, so that there is room to explore learning.
Xu Qing said that at present Watson has not connected with the HIS system of Shanghai Ten Hospitals. During the consultation, it is still necessary to input the patient's data manually.
When one hospital refused to buy Watson, it raised three points: First, Watson did not pass the certification of the regulatory authorities in the United States and China. Who would take the responsibility if something went wrong? The two is why we charge 6000 yuan to patients. Three is the concern that medical data is open to foreign enterprises.
In October 2017, CLP data and IBM set up a joint venture to provide Watson Health related solutions to the Chinese market.
Globally, Watson is still seeking more data and covering more cancer types. Watson has a huge appetite for data, which means IBM has to spend a lot of money on data acquisition for a long time.
On a global scale, only a few hospitals have purchased Watson systems, which is far from the goal of IBM
According to the STAT report, IBM failed to fully recognize the challenges of deploying to hospitals worldwide and launched an immature product precisely because of IBM's eagerness to cash in through Watson.
The pressure of liquidity is not only IBM, but also domestic agents. In 2016, Cognitive Care became WfO's local operating service provider in China; in 2017, Baiyang Pharmaceutical Group signed a contract with IBM, and Baiyang Intelligent Technology was its strategic partner in Watson Health China.
Under the background of graded diagnosis and treatment, domestic agents expect to find business opportunities in grass-roots medical institutions. The selling point is that WfO can regulate the process of cancer treatment.
However, county-level hospitals are more positioned as the diagnosis and treatment of common diseases, and the value of Watson
Sheng Nuo family and Baiyang technology to introduce the WfO, but did not really land.
At present, cognitive care and Baiyang technology have made the WfO interactive interface Chinese. Cognitive Care General Manager Hua Songyuan told the Financial Journal that hundreds of thousands of Chinese words have been translated and a set of Chinese standards have been established. However, most of the medical advice provided by IBM Watson is published in English in the top international magazines, and is not yet Chinese. This requires that doctors at the grass-roots level have a high level of English literature reading, but most of the grass-roots doctors in China are difficult to achieve.
Domestic agents need to explore Watson's domestic landing solutions, train them to grow, and find the right business model.
Despite the belief that the public was expecting too much from Watson,
From the beginning of the project, Watson's two identical agents were the main promoters in China, and both were constantly competing. Cognitive care for the "Finance" data is that WfO officially landed in more than 70 third-tier hospitals; Baiyang said that by March 2018, WfO has covered 65 hospitals and medical institutions. Globally, WfO covers more than 150 hospitals.
Watson tumor cognition includes six products, such as WfO and WfG. Baiyang Technologies and Cognitive Care Agents sell WfO, while Baiyang Technologies is the exclusive distributor of WfG in China. WfG is in the stage of programme formation and has not yet been used in large scale.
In March, Baiyang Technology and IBM announced that they will extend WfO's exclusive total distribution rights strategic cooperation agreement from three years to eight years, that is, Baiyang Technology can also choose other institutions for distribution. “If it is only three years, it may still be in development. & rdquo; Fu Gang said.
Worldwide, Watson charges range from $1,000 to $8,000, depending on the products and services it provides.
Watson charges in China range from $12,000 to tens of thousands of yuan for services such as services provided by specialists at different levels and other matching services, Huasong said.
Xu Qing said that a multi-disciplinary team of five to six doctors charged 6,000 yuan for consultation and 2,000 yuan for one or two doctors.
This is also seen as Watson is attached to the doctor to charge fees.
Since it is a doctor's tool, why do patients pay?
And Fu Gang thinks that the promotion of Watson needs a kind of
One industry insider told Finance that Baiyang Technologies lost at least 200 million yuan on IBM Watson's project. Hua Songyuan said that cognitive care now has revenue, but it is inconvenient to disclose whether it is profitable.
Watson is not approved by regulators and is seen by many doctors as the biggest risk factor.
In February 2017, the University of Texas announced the closure of the Watson partnership; in May, Chamath Palihapitiya, founder of venture capital firm Social Capital, told CNBC that Watson was a joke, and that IBM's expertise was to let consumers do it for them through strong marketing and marketing systems, and information asymmetry. Do not know the service to pay.